| Contributors: |
Laura Lagrutta, Sandra Janete Inwentarz; Denholm, Justin; Kuo Jin Teo, Alvin; Hamid Selim, Abdul; Tonmoy Kumar Dutta, Rifat Mahfuza; Skrahina, Alena; Piubello, Alberto; Rossato Silva, Denise; Ullmann De Brito Neves, Renata; Noah, Appolonie; Heffernan, Courtney; Ferrara, Giovanni; Escobar Salinas, Nadia; Peña Martinetti, Carlo; Li, Yang; Liang Li, Yu Pang; Liu, Yuhong; Torres Duque, Carlos A.; Jankovic Makek, Mateja; Ivona Markelić, Vesna Trkeš; Podlekareva, Daria; Mbuyi, Stéphane; Van Den Boom, Martin; Viiklepp, Piret; Mdluli-Dlamini (National Tuberculosis Programme, Lindiwe; Of Health, Ministry; Eswatini), Mbabane; Rafael Soto Villalta (National Tuberculosis Programme, Mario; Salvador, San; Salvador), El; Asfaw Refera (St Mary Catholic Primary Hospital, Tsion; Areka, Dubbo; Ethiopia); Kherabi (Infectious and Tropical Diseases Department, Yousra; Bernard Hospital, Bichat-Claude; Publique Hôpitaux De Paris, Assistance; Paris Cité, Université; France, Pari; Iame, Inserm; France), Pari; Tuan Dinh-Xuan (Service de Physiologie Respiratoire, Anh; Cochin, Hôpital; Lienhardt (French Institute for Research on Sustainable Development (IRD), Christian; France), Montpellier; Guitouka Strédice (Programme National de Lutte contre la Tuberculose du Gabon, Manguinga; Gabon), Libreville; Buziashvili (Department of Scientific Research, Mariana; Center For Tuberculosis And Lung Diseases, National; Georgia), Tbilisi; Manika, Katerina; Papadaki, Eleni; Vogiatzoglou (Pulmonary Department, Anastasio; University Of Thessaloniki, Aristotle; Greece), Thessaloniki; Alejandra Silvestre Tuch (National Tuberculosis Programme, Hibeb; City, Guatemala; Guatemala); Vicente Mendes (National Tuberculosis Programme, Delfim; Bissau; Bissau), Guinea; Mishra (Department of Respiratory Medicine, Gyanshankar; Gandhi Government Medical College, Indira; India), Nagpur; India), Blessina Kumar (The Global Coalition of TB Advocate; Singla, Rupak; Singla (Department of TB and Respiratory Diseases, Neeta; Institute Of Tb And Respiratory Diseases, National; Delhi, New; India); Udwadia (Department of Pulmonary Medicine, Zarir F.; Hinduja Hospital And Medical Research Centre, P. D.; India), Mumbai; Panchagnula (India), Ramesh; Bhargava (Department of Medicine, Anurag; Medical College Mangalore, Kasturba; Academy Of Higher Education, Manipal; Karnataka, Manipal; Burhan (Department of Pulmonology and Respiratory Medicine, Erlina; Of Medicine, Faculty; of Indonesia), University; Zulfriti (Department of Pulmonology and Respiratory Medicine, Diah; Society of Respirology), Indonesian; Indonesia), Yusie Permata (Damien Foundation; Alyssa Gabriella Sinuraya, Fira; Wardoyo (Respiratory Programmatic Implementation and Research Institute, Prasetio; Indonesia), Jakarta; Centis, Rosella; Battista Migliori (Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Giovanni; Clinici Scientifici Maugeri, Istituti; Tradate, Ircc; Italy); Ruffo Codecasa, Luigi; Ferrarese, Maurizio; Fumagalli (TB Reference Centre, Giovanni; Marelli Institute, Villa |
| Description: |
We read with interest the study by BÉRANGER et al. [1] and the related editorial [2], which raised once more the issue of improving existing anti-tuberculosis (TB) regimens. With 10.7 million cases and 1.23 million deaths estimated for 2024, tuberculosis (TB) remains a clinical and public health challenge [3, 4]. Poor access to TB treatment regimens and suboptimal treatment outcomes ( particularly for persons with TB/HIV co-infection and with rifampicin- and multidrug-resistant TB) underscore the urgent need for new regimens that are safe, effective, shorter and affordable. Such improvements are essential to curb the TB epidemic and prevent post-treatment sequalae [5–8]. Despite the high health burden carried by TB, the process of translating clinical trial results into programmatic action is often hampered or delayed by different factors, spanning from evidence limitations (e.g. trials that do not include country-specific data or key populations) to the complex regulatory and normative environment at national level [9–11]. In the past few years, several new drugs and regimens have entered the TB research and development pipeline for treatment of disease and infection [3–5]. To effectively translate new evidence into clinical and programmatic practice, research studies investigating end users’ needs and expectations are required. “End-users” include all the actors involved in the implementation and delivery of TB care and prevention, such as National TB Programme managers and staff, academics and scientific experts (e.g. in the field of pulmonology, infectious diseases, microbiology, paediatrics and public health), clinicians, general practitioners and other care providers, non-governmental organisation staff, and, especially, people and communities affected by TB. Engaging end-users in discussion and decision-making regarding available options also involves exploring additional dimensions of translating future evidence into policy and practice. Critical aspects include feasibility, acceptability, economic ... |